Board of Directors

Lars Lütjohan, attorney-at-law (Chairman).

Board Member (since 2016).

Extensive experience within Life Science e.g. cross-border M&A, capital markets, securities law, venture capital investments and ECM transactions regarding both publicly listed and unlisted companies. Further, he has substantial experience with IPOs and fundraising in both publicly listed and unlisted companies and has within M&A provided advise in numerous large and complicated M&A transactions, including auction processes.

Attorney-at-law(L), LL.B, Partner, Mazanti-Andersen Korsø Jensen. Admittet to the High Court (2015). BoD: Birn Foundation, Vald.Birn Holding, Abrahamsons Memorial Trust, B93 Football Club, Pantebrevselskabet CPH /S/S, Mazanti-Andersen Korsø Jensen, Ejendomsselskabet Hjallse 2014 A/S, Barir Holdingg ApS, 93 Invest Aps.

Has provided legal services to ParaTech since 2004.

Christian Kapel, professor, PhD 

Founder, CEO and CSO of ParaTech (since 2004).

10 years of experience with GMP manufacture of API for biological drugs, preclinical and clinical research within helminth therapy (TSO). 20 years of research experience within host-parasite biology, molecular diagnostics and immune stimulation (Royal Veterinary and Agricultural University DK, US Dept. of Agriculture, University of Copenhagen). Has served in the BoD of ParaTest Aps (chairman 2004-15) and ParaTech A/S (2004-).

Professor and head of the Host & Parasite research group (Organismal Biology, Faculty of Science, UC), member of Academic Council (University of Copenhagen). Advisory board of Danish Centre for Experimental Parasitology (1995-2000), Head of Studies at Faculty of Science (2003-2013). Advisory expert for the EU Commission, FAO, OIE, OECD and WHO. Over 180 scientific publications (H-index 31, +3000 citations) and has lead several national and international research projects within e.g. host-parasite biology, parasite epidemiology, clinical parasitology and molecular diagnostics. Has supervised 31 BSc students, 40 MSc students, 11 PhD students, 3 post docs. Has been awarded the Crown Prince Frederik's Award, the OECD Research and Mobility Award, and the Teacher of the Year Award (UC).

Hanne Schultz Kapel, MSc

CCO and CMO of ParaTech (since 2016)

Extensive business experience within pharma commercial roles and management. 14 years at executive level with P&L responsibility at Roche. Over 20 years in pharma marketing, sales, communication, market access, medical and medicinal information. Leadership of international projects with significant results. Therapeutic expertise: Oncology, hematology, immunology, rheumatology, pulmonology, diabetes, obesity, cardiovascular- and metabolic diseases, autoimmune diseases, virology, CNS, transplantation, anaemia, dermatology, gastroenterology, infection, allergy, osteoporosis. Since 2006 experience with biologic products (monoclonal antibodies).